Zuranolone (CAS: 1632051-40-1): A Promising Therapeutic Agent for Mental Health
Introduction: Zuranolone, with the chemical name (3α,5β,12β)-3-hydroxy-12-(pyrrolidin-1-yl)-5-(propylthio)cholan-24-oic acid methyl ester, is a novel investigational drug that has gained significant attention in the field of mental health. Developed by pharmaceutical company Sage Therapeutics, this compound shows great potential in the treatment of several psychological disorders.
Molecular Formula and Formula Weight: The molecular formula of zuranolone is C26H45NO4S, and it has a formula weight of 471.7 g/mol.
CAS Number: Zuranolone is identified by the Chemical Abstracts Service (CAS) number 1632051-40-1.
Top Ten Keywords and Synonyms:
- CAS: 1632051-40-1
- SAGE-217 (synonym)
- Neuroactive Steroid
- Major Depressive Disorder
- Anxiety Disorders
- Postpartum Depression
- GABAA Receptor Positive Allosteric Modulator
- Mental Health Treatment
- Clinical Trials
Health Benefits of Zuranolone: Clinical trials have demonstrated that zuranolone holds promise in treating various mental health conditions, including major depressive disorder (MDD), anxiety disorders, and postpartum depression. This compound acts as a positive allosteric modulator of the GABAA receptor, which helps regulate brain activity and reduce symptoms associated with these disorders. Zuranolone has shown rapid onset of effect and sustained therapeutic benefits, making it a potential game-changer in the field of mental health treatment.
Potential Effects: Zuranolone exerts its effects by enhancing inhibitory GABAergic neurotransmission in the brain, providing relief from the debilitating symptoms of depression and anxiety. By modulating the GABAA receptor, zuranolone assists in restoring the balance of brain signaling, promoting a more stable mood, and reducing excessive worry and fear.
Product Mechanism: Zuranolone is a selective and potent allosteric modulator of the GABAA receptor, one of the primary inhibitory receptors in the central nervous system (CNS). By binding to specific sites on this receptor, zuranolone enhances the inhibitory action of GABA, resulting in a calming and anxiolytic effect.
Safety: During clinical trials, zuranolone exhibited a favorable safety profile. Common adverse effects included sedation, dizziness, and nausea, which were reported to be generally mild and transient. Notably, zuranolone showed a low potential for abuse and addiction compared to other compounds used in mental health treatment.
Side Effects: While zuranolone generally poses a low risk of side effects, it is essential to note that individual responses may vary. Some reported side effects during clinical trials included headache, fatigue, and dry mouth. It is important for patients and healthcare providers to monitor for any adverse effects and promptly address them, if they occur.
Contraindications: Zuranolone is contraindicated in individuals with a known hypersensitivity to the drug or any of its components. Patients with severe liver or kidney impairment should exercise caution, as limited data is available regarding the use of zuranolone in these populations. Close consultation with a healthcare professional is advised to ensure suitability and safety.
Conclusion: Zuranolone (CAS: 1632051-40-1) represents a significant advancement in mental health treatment. With its unique mechanism of action as a GABAA receptor positive allosteric modulator, it offers an alternative therapeutic option for individuals suffering from major depressive disorder, anxiety disorders, and postpartum depression. Although further research is necessary to confirm its efficacy and long-term safety, early results are promising. Zuranolone has the potential to alleviate the burden of mental health conditions, helping individuals lead healthier and more fulfilling lives.